Summary There is emerging evidence to support the unfavorable effects of some anti-epileptic drugs on the plasma homocysteine concentrations. Elevated homocysteine levels induced by anti-epileptic drug administration can theoretically increase not only the risk of vascular occlusive diseases, but also the risk of resistance to anti-epileptics and development of refractory epilepsy. To investigate the effect of common anti-epileptic drugs on the homocysteine metabolism, a total of 75 epileptic patients receiving phenytoin (n = 16), carbamazepine (n = 19), or valproic acid (n = 22) and no anti-epileptic drug (n = 18) were enrolled. Eleven age-and sexmatched healthy subjects served as the control group. Blood concentrations of homocysteine, folic acid, Vitamin B12 and pyridoxal 5 0 -phosphate (active circulating form of Vitamin B6) were measured. Compared to the control group, epileptic patients on anti-epileptic drug had higher blood levels of homocysteine. No difference in homocysteine concentrations was observed among epileptic patients in terms of the anti-epileptic drug used. Patients receiving phenytoin had significantly lower folic acid levels and those receiving carbamazepine had marginally lower pyridoxal 5 0 -phosphate levels in comparison with those using other anti-epileptic drugs. A negative correlation between homocysteine and folic acid concentrations was detected in epileptic patients on anti-epileptic drug. The duration of anti-epileptic drug use was correlated to the decrease of folic acid levels, but not with changes observed in homocysteine, Vitamin B12 and pyridoxal 5 0 -phosphate levels. No relationship between seizure frequency and homocysteine levels was observed in epileptic patients. Our results confirm that common anti-epileptic drugs has disadvantageous
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Introduction
Homocysteine is an amino acid formed during the methionine metabolism. In the cells, almost half of the homocysteine is used in cysteine synthesis via transsulfuration by a Vitamin B6 dependent enzyme, cystathionine beta-synthase. Deficiency of this enzyme results in homocystinuria, in which homocysteine blood levels are significantly increased. Major clinical manifestations involve the eyes and the central nervous, skeletal and vascular systems. Of note, the incidence of seizures is increased up to 20% in patients with homocystinuria. 1 The other half of the homocysteine is normally remethylated to methionine, with folic acid, Vitamin B2 and Vitamin B12 as cofactors. Homocysteine concentrations increase mildly in the deficiency of these vitamins. This is a more common form of hyperhomocysteinemia, which is a well-established risk factor for vascular disease via homocysteine associated vascular endothelial damage resulting in acceleration of atherosclerosis and alterations of the blood coagulation system leading to prothrombotic state. [2] [3] [4] However, its relation to epilepsy has not been clearly demonstrated.
Patients on anti-epileptic drugs are prone to high concentrations of plasma homocysteine and low status of folate and Vitamin B6. [5] [6] [7] The consequences of this metabolic disturbance may be of clinical importance. First, in addition to its adverse effects on atherogenic lipid levels, 8, 9 increased homocysteine levels associated with anti-epileptic drugs may be a risk factor for systemic vascular events including stroke. Because the use of the anti-epileptic drug may be extended over years, chronic vascular toxicity may be an important concern. Second, increased homocysteine and low folate status may contribute to the development of anti-epileptic drug related side effects, such as impaired cognitive function and fetal malformations including neural tube defect, 10, 11 for which hyperhomocysteinemia is an established independent risk factor. 12, 13 Third, and the most speculative, increased homocysteine may also be involved in poor seizure control in epileptic patients, based on the fact that its systemic application is known to cause an animal model of epilepsy. 14 In this study, our main intention was to assess the effect of monotherapy with common anti-epileptic drugs on the homocysteine metabolism. We also attempted to uncover the relationship between the levels of homocysteine, with the cofactors involved in its metabolism, and epilepsy control in addition to other clinically relevant parameters.
Patients and methods

Study population
Seventy-five patients with the diagnosis of idiopathic generalized epilepsy, followed at the Department of Neurology in SSK Tepecik Teaching Hospital, were studied. The non-anti-epileptic group consisted of 18 patients, including 15 patients with newly diagnosed epilepsy and 3 patients who had not been taking any medicine for their epilepsy for the last 2 years. There were 11 female and 7 male in this group. The mean age was 30 AE 12 (range 17-45) years. Fifty-seven patients were receiving anti-epileptic drug monotherapy (anti-epileptic drug group: carbamazepine (n = 19), valproic acid (n = 22) and phenytoin (n = 16). Age-and sex-matched 11 healthy volunteers were included into the study as control group. The mean age of the patients and controls was 29 AE 11 (range 16-56) and 32 AE 6 (range 25-41) years, respectively. Fourtyone (55%) of the total patients and 7 (64%) of the controls were female. The mean duration of treatment of patients receiving anti-epileptic drug was 6.5 AE 6.2 (range 1-26) years. No significant difference among patients receiving anti-epileptic drug was observed in terms of age, gender and duration of treatment ( p > 0.05).
In all patients, serum levels of anti-epileptic drugs were measured in the same blood samples obtained for homocysteine, Vitamin B12, pyridoxal 5 0 -phosphate (active circulating form of Vitamin B6) 80 U. Sener et al.
effects on homocysteine status. Because there was no significant change in homocysteine concentrations in epileptic patients who were not receiving an anti-epileptic drug, and no positive correlation between seizure frequency and homocysteine levels, we suggest that increase of homocysteine levels may be due to anti-epileptic drug use, rather than being epileptic in origin. Additionally, the underlying mechanism for homocysteine increase seems to be a decrease of cofactor molecules in patients using carbamazepine and phenytoin (pyridoxal 5 0 -phosphate and folic acid, respectively). However, changes observed are not related to the alteration in the levels of cofactors and remain unclear in the patients using valproic acid. # 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. and folic acid. All patients included in this study had serum levels of anti-epileptic drug within the therapeutic range.
Presence of epilepsy due to ischemic stroke, history of cardiac and peripheral vascular disease, diabetes mellitus, anemia, pregnancy and renal or thyroid disease were exclusion criteria. Subjects using folic acid antagonists and vitamins, as well as vegetarians were also excluded. Patients with silent brain infarction on magnetic resonance imaging were excluded, as well. Seizure frequency was calculated by dividing the total number of seizures to the duration of disease. The duration of epilepsy in untreated patients was shorter than those in the treated patients (6 AE 8 years versus 11 AE 8 years).
Biochemical analysis
Following an overnight fasting period, blood samples were obtained between 8 and 10 a.m. before receiving the morning dose of the anti-epileptic drug. Venous blood was taken from the antecubital vein in the sitting position. Serum was immediately separated by centrifugation after discharging. The supernatant was removed and stored at À20 8C until assayed.
Serum homocysteine, Vitamin B12 and folic acid concentrations were measured by immunoassay method using commercial kits (Immulite 1 , DPC, United States). Reference values for the kits were 5-12 mmol/L for homocysteine, 3-17 ng/mL for folic acid and 100-700 pg/mL for Vitamin B12. The values above the 12 mmol/L were accepted as hyperhomocysteinemia. Pyridoxal 5 0 -phosphate concentrations were measured by high performance liquid chromatography (HPLC; Millipore 1 ; Waters 625 LC system, United States) using commercial kits purchased from Chromsystems Diagnostics (Germany). The flurometer was set at 370 nm excitation with emission monitored at 470 nm. Flow rate was adjusted, as 1.3 mL/min. Reference values were 3.6-18 ng/mL. Anti-epileptic drug serum concentrations were determined by enzyme multiplied immunochemical technique.
Statistical analysis
Distribution of every variable was assessed using the Kolmogorov-Smirnov's test. Analyses of parametric variables were performed using one-way variance analysis (ANOVA) with post hoc Benferroni's test. In analyses of non-parametric variables, KruskalWallis test with post hoc Mann-Whitney U-test was used. Furthermore, a multivariate analysis with general linear modelling was performed to adjust the effects of age and sex on the parameters studied. For this method, both of ''F'' and ''p'' values were reported in the results. In correlation of homocysteine with the other variables, Pearson's and Spearman's correlation tests were used in each group as appropriate. Numerical data were shown as ''mean AE standard deviation (S.D.)''. Statistical significance level was set at p < 0.05. For multiple comparisons, significance level was defined as p < 0.05/''number of comparisons''.
Results
Hemoglobin and hemotocrit levels, renal and liver function tests were in normal limits in all groups. Of note, serum creatinine concentrations were normal, and did not show any correlation to the parameters (data not shown).
Homocysteine
In all groups, homocysteine levels were between 2.6 and 44.7 mmol/L except one patient using carbamazepine. In this patient, homocysteine level was measured as 100 mmol/L.
The percentage of subjects with hyperhomocysteinemia, defined as homocysteine concentration more than 12 mmol/L, was significantly higher in the anti-epileptic drug group (64%) in comparison with non-anti-epileptic drug and control groups (20%) and (27%), respectively.
Mean homocysteine level was higher in anti-epileptic drug group than in non-anti-epileptic drug and control groups ( p < 0.05) ( Table 1 ). This significant difference was found across all anti-epileptic subgroups, namely valproic acid, carbamazepine and phenytoin users, when compared to the values obtained in non-anti-epileptic drug groups. There was no significant difference among the anti-epileptic drug subgroups, when compared to each other.
After adjustment of age and sex with multivariate modelling, the significance of the differences persisted. In detail, with this statistical methodology, significantly higher homocysteine levels were again found in patients using any anti-epileptic medications (F = 7.378, p < 0.05); in those using carbamazepine (F = 7.39, p < 0.05), valproic acid (F = 9.745, p < 0.05) and phenytoin (F = 9.745, p < 0.05).
No difference was observed between mean homocysteine concentrations measured in the non-anti-epileptic drug group and controls.
Folic acid
After adjustment for age and sex, patients on antiepileptic drugs had significantly lower folic acid levels compared to the control group (F = 4.817, p < 0.05). Considering the anti-epileptic medication subgroups, folic acid levels differed only in patients using phenytoin (F = 11.8, p < 0.05) and were found not to be different in valproic acid (F = 1.38, not significant (NS)) and carbamazepine users (F = 0.902, NS). There was no difference in folic acid levels among non-anti-epileptic drug and control groups.
Vitamin B6 (pyridoxal 5
0 -phosphate)
Mean pyridoxal 5 0 -phosphate level was lower in antiepileptic drug group than those in non-anti-epileptic drug group and the control ones. Unfortunately, after adjustment for age and sex, the observed differences on univariate analyses did not persist. The only difference was that the patients taking carbamazepine showed a tendency for decreased level of pyridoxal 5 0 -phosphate (F = 0.597, p = 0.062).
Vitamin B12
No difference was found among the entire study population ( p = 0.701, p = 0.357), or in anti-epileptic drug subgroup compared to the controls on uniand multivariate analyses.
Association of homocysteine with folic acid, pyridoxal 5 0 -phosphate and Vitamin B12 A significant negative correlation was found between the levels of homocysteine and folic acid (r = À0.332, p < 0.05) in patients using anti-epileptic drugs and in entire study population (r = À0.410, p < 0.05) (Fig. 1) . No association was found between homocysteine and pyridoxal 5 0 -phosphate as well as homocysteine and Vitamin B12.
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U. Sener et al. Association of the levels of homocysteine, folic acid, pyridoxal 5 0 -phosphate and Vitamin B12 with the duration of treatment and disease There was a negative correlation between the duration of treatment and folic acid levels in the antiepileptic drug group (r = À0.27, p = 0.045). No correlation was found between the levels of homocysteine, pyridoxal 5 0 -phosphate, Vitamin B12 and the duration of treatment and the disease ( p > 0.05).
Relationship between seizure frequency and the level of homocysteine
There was no significant association between the seizure frequency and the level of homocysteine. Also, there was no difference in homocysteine concentrations between patients who remained seizure free and the patients who had at least one seizure during the last year or the last 3 months.
Discussion
The relationship between increased homocysteine level and epileptic seizure remains controversial in humans despite a growing evidence of the pro-convulsive effect of the hyperhomocysteinemia observed in the animal studies. The mechanism of this association with epileptogenesis has not been clearly understood, but some evidence is available. Homocysteine and its oxidative product, homocysteic acid, are potent agonists of the N-methyl-Daspartate (NMDA)-type glutamate receptor, which are linked with epileptogenesis. 15 Furthermore, there is some data from animal studies demonstrating that homocysteine sequesters adenosine, an endogenous anti-convulsant and thereby reduces the seizure threshold. 16 Additionally, up to 20% of patients with homocystinuria have seizures 1 and high plasma concentrations of homocysteine (50-200 mmol/L) have been reported in these patients. 17 And, Ono et al. 18 also reported that seizures could not be controlled optimally when the homocysteine level is above 20 mmol/L. These data suggest that increased homocysteine levels may be related to epileptogenesis and/or sub-optimal control of seizures in the patients with epilepsy. We tried to answer this question by including untreated epilepsy patients (the non-anti-epileptic drug group) into the study and by correlating seizure frequency to homocysteine levels in the epileptic patients studied. As a result, no difference was observed between the measured mean homocysteine concentrations of non-anti-epileptic drug and control groups. Also, no positive correlation of increased homocysteine levels to seizure frequency was detected in epileptic patients. These observations support the hypothesis of Ono et al. 18 that a milder increase, less than 20 mmol/L, in homocysteine levels may not be unfavorable in seizure control. At this point, our study provides more reliable data, because, unlike nonhomogeneity of patients studied by Ono et al. 18 in terms of epilepsy etiology and anti-epileptic drugs used, our study population is quite homogenous (all were with idiopathic epilepsy and were receiving monotherapy).
Data regarding anti-epileptic drugs and their effect on homocysteine metabolism have been controversial. Schwaninger et al. 5 and Ono et al. 18, 19 reported that anti-epileptic drugs elevated homocysteine concentrations in patients on polytherapy. However, no strict agreement is available on patients receiving monotherapy. Some studies reported elevated homocysteine levels with carbamazepine 6, 7, 20, 21 and valproic acid 6, 7, 21 use. However, others reported no changes in homocysteine levels with carbamazepine 5 and valproic acid. 22 Our study results are in agreement with the previous reports which have found high homocysteine concentrations in patients receiving monotherapy. Furthermore, our data showed that a significant proportion (almost half) of the epileptic patients taking anti-epileptic drug have abnormally increased homocysteine levels. Because we studied both epileptic patients not receiving anti-epileptic drugs and healthy controls, and demonstrated that there were no differences in homocysteine levels between them, we think that we have successfully excluded the effects of being epileptic on homocysteine status which has not been considered in most of the studies. For this reason, we suggest that the drugs, rather than the disease, play a major role in the development of hyperhomocysteinemia in epileptic patients.
Little is known about how phenytoin, carbamazepine and valproic acid exert their effects on homocysteine metabolism. It has been suggested that phenytoin and carbamazepine, as enzyme inducers, can directly modulate the activity of different liver enzymes. 23 Liver enzyme induction may cause depletion of the cofactor involved, folic acid, pyridoxal 5 0 -phosphate and Vitamin B12, leading to the alterations observed in homocysteine status. It is well-known that patients on phenytoin often have low serum folic acid levels. Data from several investigations showed that valproic acid is associated with either low 6, 7 or normal 22 folic acid levels. Some studies also revealed that carbamazepine use was associated with low folic acid status. 6, 7, 20 In our study, the patients receiving phenytoin had lower folic acid levels in comparison to the control groups. The data regarding Vitamin B12 status after antiepileptic drug use is also conflicting. Studies showed decreased 21 and normal [5] [6] [7] Vitamin B12 levels in epileptic patients using carbamazepine, and normal 7, 21 or increased 6 Vitamin B12 levels associated with valproic acid use. In our study, there was no difference in Vitamin B12 levels of the anti-epileptic drug, non-anti-epileptic drug and control groups. In association with use of valproic acid and carbamazepine, pyridoxal 5 0 -phosphate levels have been reported to be decreased in most of the studies on record. [5] [6] [7] Our results are somewhat supportive of this association with carbamazepine. Even though no changes in gamma-glutamyl transferase concentrations as a sign of enzyme induction were observed, we still consider that hyperhomocysteinemia can be secondary to reduced cofactor levels (folic acid and possibly pyridoxal 5 0 -phosphate levels in the patients receiving phenytoin and carbamazepine, respectively). Evidently, valproic acid does not have a similar effect on liver enzymes. It is probably for this reason that our patients, receiving valproic acid, did not have reduced levels of cofactors. This observation indicates that in valproic acid treated patients another mechanism, unrelated to cofactors, may take role in the development of hyperhomocysteinemia.
It has been shown that blood concentration of folic acid is inversely related to the blood concentration of homocysteine. On the other hand, the relationship of homocysteine levels to pyridoxal 5 0 -phosphate and Vitamin B12 status is not clear. 24, 25 In our study, a negative correlation was only found between folic acid and homocysteine levels. The level of folic acid was negatively correlated with duration of treatment. However, we did not find any correlation between the duration of treatment and the levels of homocysteine. This is in accordance with some, 26 but not all studies. 6, 19 In conclusion, hyperhomocysteinemia is much more prevalent in the patients using anti-epileptic drugs. It has been reported that increased homocysteine level can be lowered with supplementation of its cofactors, folic acid, Vitamin B12 and Vitamin B6. 27 Supplementation is inexpensive, effective and devoid of adverse effects and, therefore, has an exceptionally favorable benefit/risk ratio. Reduction of elevated plasma homocysteine concentrations to less than 10 mmol/L may theoretically prevent up to 25% of cardiovascular events. Until the results of ongoing randomized controlled trials become available for beneficial effect of screening and treatment of hyperhomocysteinemia, recommendation for the apparently healthy general population may not be advisable. However, because of the high frequency in patients receiving anti-epileptic drug therapy, we suggest that homocysteine levels should be routinely screened in all, and be treated when its level is found to be high. This approach may be more relevant particularly in some epileptic patient groups, such as pregnant epileptic patients because of a possible relation with neural tube defect.
